Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab plus trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR-trial

被引：4
|
作者：
Gluz, Oleg [1 ,2 ,3 ]
Kolberg-Liedtke, Cornelia [4 ]
Biehl, Claudia [5 ]
Christgen, Matthias [6 ]
Kuemmel, Sherko [7 ]
Grischke, Eva -Maria [8 ]
Augustin, Doris [9 ]
Braun, Michael [10 ]
Potenberg, Jochem [11 ]
Graeser, Monika
Kates, Ronald
Wuerstlein, Rachel [12 ,13 ]
Feuerhake, Friedrich [14 ]
Nitz, Ulrike [1 ,2 ]
Kreipe, Hans
Harbeck, Nadia [12 ,13 ]
机构：
[1] West German Study Grp, Monchengladbach, Germany
[2] Breast Ctr Niederrhein Johanniter Clin, Monchengladbach, Germany
[3] Univ Clin Cologne, Monchengladbach, Germany
[4] Charite Univ Med Berlin, Campus Mitte, Berlin, Germany
[5] City Hosp Dortmund, Westphalian Breast Ctr, Dortmund, Germany
[6] Med Sch Hannover, Inst Pathol, Hannover, Germany
[7] Breast Ctr, Clin Essen Mitte, Essen, Germany
[8] Womens Clin, Univ Clin Tuebingen, Tubingen, Germany
[9] Breast Ctr Ostbayern, DONAUISAR Clin Deggendorf, Deggendorf, Germany
[10] Rotkreuzklinikum Munich, Breast Ctr, Munich, Germany
[11] Evangel Waldkrankenhaus, Dept Oncol, Berlin, Germany
[12] Univ Munich LMU, Breast Ctr, Munich, Germany
[13] CCCLMU, Munich, Germany
[14] Med Sch Hannover, Inst Pathol, Monchengladbach, Germany
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P4-10-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-10-05
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab plus trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
    Graeser, M.
    Gluz, O.
    Biehl, C.
    Ulbrich-Gebauer, D.
    Palatty, J.
    Christgen, M.
    Kuemmel, S.
    Grischke, E-M.
    Augustin, D.
    Braun, M.
    Potenberg, J.
    Wuerstlein, R.
    Eulenburg, C.
    Kates, R.
    Kolberg-Liedtke, C.
    Feuerhake, F.
    Kreipe, H.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S48 - S48
  • [2] Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial
    Biehl, Claudia
    Kolberg-Liedtke, Cornelia
    Gluz, Oleg
    Feuerhake, Friedrich
    Christgen, Matthias
    Kates, Ronald
    Grischke, Eva-Maria
    Forstbauer, Helmut
    Braun, Michael
    Warm, Mathias
    Hackmann, John
    Uleer, Christoph
    Aktas, Bahriye
    Schumacher, Claudia
    Kuemmel, Sherko
    de Haas, Sanne L.
    Deurloo, Regula
    Wuerstlein, Rachel
    Nitz, Ulrike
    Kreipe, Hans H.
    Harbeck, Nadia
    CANCER RESEARCH, 2020, 80 (04)
  • [3] De-escalated neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel weekly in HR-/HER2+early breast cancer: ADAPT-HR-/HER2+biomarker and survival results.
    Harbeck, Nadia
    Gluz, Oleg
    Christgen, Matthias
    Kuemmel, Sherko
    Grischke, Eva-Maria
    Braun, Michael
    Potenberg, Jochem
    Krauss, Katja
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Stefek, Andrea
    Fischer, Hans Holger
    Pelz, Enrico
    Graeser, Monika
    zu Eulenburg, Christine
    Kates, Ronald E.
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
    Nitz, Ulrike
    Gluz, Oleg
    Graeser, Monika
    Christgen, Matthias
    Kuemmel, Sherko
    Grischke, Eva-Maria
    Braun, Michael
    Augustin, Doris
    Potenberg, Jochem
    Krauss, Katja
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Stefek, Andrea
    Fischer, Hans Holger
    Pelz, Enrico
    Zu Eulenburg, Christine
    Kates, Ronald
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    LANCET ONCOLOGY, 2022, 23 (05): : 625 - 635
  • [5] Final analysis of WSG-ADAPT HER2+/HR-trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab plus pertuzumab weekly paclitaxel in HER2+/HR-early breast cancer (EBC).
    Nitz, Ulrike
    Gluz, Oleg
    Christgen, Matthias
    Grischke, Eva -Maria
    Augustin, Doris
    Kummel, Sherko
    Braun, Michael Wilhelm
    Potenberg, Jochem
    Kohls, Andreas
    Krauss, Katja
    Stefek, Andrea
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Fischer, Hans Holger
    Liedtke, Cornelia
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] De-escalated chemotherapy versus endocrine therapy plus pertuzumab plus trastuzumab for HR+/HER2+early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.
    Gluz, Oleg
    Nitz, Ulrike
    Christgen, Matthias
    Kuemmel, Sherko
    Holtschmidt, Johannes
    Priel, Jan
    Hartkopf, Andreas
    Potenberg, Jochem
    Luedtke-Heckenkamp, Kerstin
    Just, Marianne
    Wuelfing, Pia
    Von Schumann, Raquel
    Graeser, Monika
    Wuerstlein, Rachel
    Kates, Ronald E.
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] The predictive value of tumor-infiltrating lymphocytes and PD-L1 expression on the efficacy of neoadjuvant trastuzumab plus chemotherapy in HER2-positive breast cancer
    Li, Huihui
    Shang, Mao
    Chi, Yajing
    Yin, Sha
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial
    Graeser, Monika
    Gluz, Oleg
    Biehl, Claudia
    Ulbrich-Gebauer, Daniel
    Christgen, Matthias
    Palatty, Jenci
    Kuemmel, Sherko
    Grischke, Eva -Maria
    Augustin, Doris
    Braun, Michael
    Potenberg, Jochem
    Wuerstlein, Rachel
    Krauss, Katja
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Stefek, Andrea
    Fischer, Hans Holger
    Pelz, Enrico
    zu Eulenburg, Christine
    Kates, Ronald
    Ni, Hua
    Kolberg-Liedtke, Cornelia
    Feuerhake, Friedrich
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Harbeck, Nadia
    CLINICAL CANCER RESEARCH, 2023, 29 (04) : 805 - 814
  • [10] Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial
    Gluz, O.
    Nitz, U. A.
    Christgen, M.
    Kummel, S.
    Holtschmidt, J.
    Schumacher, J.
    Hartkopf, A. D.
    Luedtke-Heckenkamp, K.
    Just, M.
    von Schumann, R.
    Polata, S.
    Schinkoethe, T.
    Graeser-Mayer, M. K.
    Kates, R. E.
    Wuerstlein, R.
    Kreipe, H.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2024, 35 : 1210 - 1210
12345